Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10.

Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA.

J Mol Biol. 2007 Feb 2;365(5):1533-44. Epub 2006 Nov 10.

PMID:
17125793
2.
3.

Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.

Wu L, Yang ZY, Xu L, Welcher B, Winfrey S, Shao Y, Mascola JR, Nabel GJ.

Vaccine. 2006 Jun 5;24(23):4995-5002. Epub 2006 Apr 18.

PMID:
16690178
4.

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.

5.

Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, Dawson PE.

J Virol. 2006 Feb;80(4):1680-7.

7.

Structure of a V3-containing HIV-1 gp120 core.

Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD.

Science. 2005 Nov 11;310(5750):1025-8.

8.

Antibody vs. HIV in a clash of evolutionary titans.

Burton DR, Stanfield RL, Wilson IA.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8. Epub 2005 Oct 11. Review.

9.

The 2F5 epitope is helical in the HIV-1 entry inhibitor T-20.

Biron Z, Khare S, Quadt SR, Hayek Y, Naider F, Anglister J.

Biochemistry. 2005 Oct 18;44(41):13602-11.

PMID:
16216084
10.

Comparing antigenicity and immunogenicity of engineered gp120.

Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR.

J Virol. 2005 Oct;79(19):12148-63.

11.
12.

Enhancement of immune responses to an HBV DNA vaccine by electroporation.

Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R.

Vaccine. 2006 May 22;24(21):4490-3. Epub 2005 Aug 19.

PMID:
16140436
13.
14.

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC.

J Virol. 2005 Aug;79(16):10108-25.

15.

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, Petropoulos CJ, Polonis VR, Sarzotti M, Montefiori DC.

J Virol. 2005 Aug;79(16):10103-7. No abstract available.

16.

The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, Cheng-Mayer C, Stamatatos L.

J Virol. 2005 Jul;79(14):9069-80.

17.

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

Beddows S, Sch├╝lke N, Kirschner M, Barnes K, Franti M, Michael E, Ketas T, Sanders RW, Maddon PJ, Olson WC, Moore JP.

J Virol. 2005 Jul;79(14):8812-27.

18.
20.

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM.

Science. 2005 Jun 24;308(5730):1906-8. Epub 2005 Apr 28.

Supplemental Content

Support Center